Steven Morgan
Psychiatry · Bristol, TNNPI 1003809781
Payments from drug & device makers
Across 153 payments — averaging $17.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$338
- UCB, Inc.$267
- Novartis$207
- Lilly USA, LLC$181
- Biogen$179
- AstraZeneca$164
- plus $1K from 31 others
What the payments were for
- Food & beverage$2,682100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 22 | $338 |
| UCB, Inc. | 12 | $267 |
| Novartis | 12 | $207 |
| Lilly USA, LLC | 11 | $181 |
| Biogen | 10 | $179 |
| AstraZeneca | 7 | $164 |
| Eisai Inc. | 6 | $110 |
| Johnson & Johnson | 6 | $94 |
| Sunovion Pharmaceuticals Inc. | 6 | $92 |
| Acadia Pharmaceuticals Inc | 6 | $90 |
| MDD US Operations, LLC | 5 | $85 |
| Adamas Pharmaceuticals, Inc. | 4 | $75 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $67 |
| Sanofi | 3 | $58 |
| Argenx US, Inc. | 3 | $56 |
| Lundbeck LLC | 3 | $52 |
| Avanir Pharmaceuticals, Inc. | 3 | $51 |
| Neurocrine Biosciences, Inc. | 3 | $45 |
| Ipsen Biopharmaceuticals, Inc | 2 | $44 |
| Amgen | 2 | $42 |
| Mallinckrodt Enterprises LLC | 2 | $41 |
| Akcea Therapeutics, Inc. | 2 | $34 |
| Kyowa Kirin, Inc. | 1 | $30 |
| Arbor Pharmaceuticals, Inc. | 2 | $29 |
| Neurelis, Inc. | 1 | $28 |
| Greenwich Biosciences, Inc. | 1 | $28 |
| Amneal Pharmaceuticals LLC | 2 | $27 |
| Livanova USA, Inc. | 2 | $26 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $21 |
| Supernus Pharmaceuticals, Inc. | 1 | $21 |
| CSL Behring | 1 | $19 |
| Pfizer | 1 | $17 |
| USWM, LLC | 1 | $15 |
| Assertio Therapeutics, Inc. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| EMD Serono, Inc. | 1 | $13 |
| Biohaven Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$2,682 in reported general payments places this provider in the 75th percentile of 503 psychiatry providers in Tennessee.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 90 | $9,466 |
| Buprenorphine Hcl | 28 | $699 |
| Methylphenidate Hcl | 11 | $687 |
| Duloxetine Hcl | 22 | $372 |
| Aripiprazole | 17 | $368 |
| Alprazolam | 73 | $356 |
| Clonazepam | 33 | $329 |
| Bupropion Hcl SrBupropion Hcl | 13 | $312 |
| Gabapentin | 28 | $298 |
| Diazepam | 13 | $256 |
| Zolpidem Tartrate | 14 | $134 |
| Trazodone Hcl | 11 | $20 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Bristol
- Adrian BucknerBristol$64K
- Rakesh AminNashville$3M
- Brian BonfardinJohnson City$2.6M
- Paul NewhouseNashville$1.4M
- John FenleyJohnson City$1.4M
- Anita VarmaMemphis$1.3M
- Patricia AndrewsNashville$748K
- David SnowMaryville$605K
- Jonathan BeckerBrentwood$261K
- Robert FallisNashville$241K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.